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A recent study published by the Manhattan Institute
“Why Has Longevity Increased More in Some States
than in Others? The Role of Medical Innovation and
Other Factors,” purported to show that the more rapid
adoption of new drugs has substantial benefits in the
form of increased life expectancy, higher productivity
and lower non-drug health care expenditures. This
study has been cited as evidence supporting the more
rapid acceptance of new drugs in Medicaid, Medicare,
and other public programs and has helped to shape
public debate on the value of new drugs. This analysis
questions the key conclusions of the study. It points out
that the key statistical regressions appear to be mis-
specified, since they show anomalies such as a negative
correlation between income growth and life expectancy
and find no relationship between education and pro-
ductivity growth. Methodological flaws addressed in-
clude lack of adjustment for infant mortality rates;
inadequate proxy measures of health status; lack of
adjustment for ages of individuals and other sociodemo-
graphic factors; inherent problems with the definition of
drug age, or ‘vintage;’ and the failure to consider reverse
causation as an obvious explanation for several findings.
The Manhattan Institute study does not provide reliable
evidence for favoring adoption of newer drugs in either
public or private health care programs.
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D
etermining the value of drugs is important for both
payers and policymakers. Prescription drugs account for
about 10% of health care spending.
1 Newer, branded drugs
contribute the lion’s share of prescription expenses. However,
the Pharmaceutical Research and Manufacturers Association
claims that new drugs prevent hospitalizations and surgeries
and “play a significant role in the life expectancy gains made in
the United States and around the world.”
2
Many citations for claims that improved health offset the
higher costs of new drugs can be traced back to studies by
Frank Lichtenberg, an economist. Dr. Lichtenberg’sw o r k
includes at least a dozen studies, mostly released as working
papers, that purport to demonstrate the economic benefits of
new drugs in the U.S. and other countries.
3 Although his
methodology has been criticized,
4–7 Lichtenberg’s studies have
been influential in persuading policymakers that new, expen-
sive drugs are cost-effective.
4 For example, a Congressional
Budget Office Report, Issues in Designing a Prescription Drug
Benefit for Medicare, while noting methodological limitations of
the studies cited, concludes that, “Nevertheless, the magni-
tude of the net savings estimated by Lichtenberg suggests that,
on balance, patients who took newer drugs were likely to spend
less on other kinds of medical care.”
8
This paper offers a critique of the theoretical foundation, the
model and the external validity of the analysis presented in one
Lichtenberg study that purports to show that rapid adoption of
new drugs lengthens lives.
9 “Why Has Longevity Increased
More in Some States than in Others? The Role of Medical
Innovation and Other Factors,” published by the Manhattan
Institute, compared, by state, increases in life expectancy (at
birth and at age 65), productivity, and various measures of
health care costs. Adjustments were made for the incidence of
AIDS, obesity, smoking, education levels, and income. The
analyses include variables intended to pick up effects specific
to a particular year (for example, an influenza epidemic) or to a
specific state (for example, a newly instituted seat belt law).
The rate of adoption of new prescription drugs in each state
was calculated using 2004 payment information from state
Medicaid programs and Medicare. The study concludes that
new drugs enhance life expectancy and growth in productivity
(dollar value of output per worker).
Methodological flaws that we will address include lack of
adjustment for infant mortality rates; inadequate proxy mea-
sures of health status; lack of adjustment for ages of indivi-
duals and other sociodemographic factors; inherent problems
with Lichtenberg’s definition of drug age, or “vintage;” and the
failure to consider reverse causation (the assumption that A
causes B when B actually causes A) as an obvious explanation
for several findings. Finally, we discuss some of the anomalous
results in Lichtenberg’s analyses.
LACK OF ADJUSTMENT FOR INFANT MORTALITY
The Manhattan Institute analysis attributes differences in life
expectancy between states to new drugs while failing to control
for infant mortality, the single most important determinant of
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678life expectancy. Because life expectancy is calculated as an
average, death rates in younger age groups have the greatest
impact. In the 19th century, when infant deaths were common,
life expectancy in 1900 was only 49.24 years. Plunging infant
mortality rates (IMRs) increased life expectancy to 68.07 years
in 1950 and 75.37 years in 1990.
10 Between 1990 and 2004,
life expectancy increased to 77.9 years.
11
Disparities in IMRs could account for most differences in
longevity in Lichtenberg’s analysis (see Fig. 1). Today, the
average IMR in the U.S. is 7.1 per 1000 births, but rates range
from a low of 4.9 in New Hampshire to a high of 13.5 in the
District of Columbia.
10 Centers for Disease Control data show
that IMRs ranged from 5.0–7.2 in the ten states noted by
Lichtenberg to have the longest life expectancy. The ten states
with the shortest life expectancy had IMRs ranging from 7.1 to
10.4.
412 Infant mortality affects life expectancy at birth but not
at age 65, which is consistent with the far greater differences
reported for life expectancy at birth than at age 65 in the
Lichtenberg report.
INADEQUATE PROXY MEASURES OF HEALTH STATUS
The Manhattan Institute study adjusted for AIDS, obesity, and
smoking — an unusual set of variables. Drug therapy has
indisputably increased the lifespan of people with AIDS.
However, AIDS is not among the 15 leading causes of death
in any state in the U.S., so has a dubious role in this type of
analysis. Obesity and smoking are risk factors for numerous
diseases, but are not acceptable surrogate markers for causes
of death.
SOCIODEMOGRAPHIC FACTORS
Ethnicity, education, income, and other sociodemographic
factors are associated with differences in life expectancy. [13]
In 2003, there was a gap of 5.3 years between blacks and
whites in life expectancy at birth, primarily due to differences
in death rates from homicide, heart disease, and HIV.
14 In
2000, a 25-year-old with a high school degree or less could
expect to live another 50 years, while someone who had
attended college could expect to live almost another 57 years.
15
Differences in sociodemographic factors across states could
thus contribute to differences in longevity.
DRUG ‘VINTAGE’
The measure of drug age in the Manhattan Institute report is
the average year in which the active ingredients in prescription
drugs were first approved by the Food and Drug Administra-
tion (FDA). This idiosyncratic measure, termed ‘drug vintage,’
cannot accurately assess the rate of adoption of new drugs
because two-thirds of what are considered ‘new drugs’ are
actually different doses, formulations, or combinations of older
drugs. Only a third of new drug approvals involve novel drugs,
also called ‘new molecular entities.’
16
Under Lichtenberg’s scheme, three ‘new’ drugs approved by
the FDA in 2004 could have three vintages. A novel drug would
be 2004 vintage. A new formulation of a drug approved in 1980
would be 1980 vintage. And a new combination of a drug
approved in 1980 with a second drug approved in 2000 would
be categorized as a 1990 vintage. The fact that two-thirds of
new drugs would be classified as older drugs confounds any
conclusions about new drugs.
Grouping drugs by age rather than effect is odd; a new acne
drug is unlikely to affect lifespan. It would have made more
sense to limit this analysis to drugs that affect mortality.
REVERSE CAUSATION
Reverse causation is not effectively controlled for in the
analysis, and could explain several key findings. Rather than
new drugs extending lives, older people may use newer drugs.
Yet, Lichtenberg’s analysis does not control for age. During the
years covered by Lichtenberg’sa n a l y s e s( w h i c hp r e - d a t e
Medicare Part D), drugs paid for by Medicare were newer than
drugs paid for by Medicaid in every state as revealed in Table 5
of Lichtenberg’s paper.
9 The gap between the mean age of
Medicare and Medicaid-covered drugs within some states was
as high as eight years — more than twice the difference in age
observed across states for Medicare— or Medicaid— covered
drugs. This suggests that Medicare recipients, primarily adults
over age 65, used newer drugs more often than younger adults
who received drugs only through Medicaid, which covers poor
people.
State-to-state variation in the use of specific drugs could
also affect the Manhattan Institute’s findings. For example,
hydrocodone/acetaminophen preparations were two of the ten
best-selling drugs between 2002 and 2006.
17 These are old
drugs: acetaminophen was first approved by the FDA in 1951;
hydrocodone, an opiate, was first used in cough syrups in the
1930s. Differences in hydrocodone/acetaminophen usage
Figure 1. The Relationship Between Infant Mortality Rates and Life
Expectancy at Birth in the United States. r
2=0.58. P<0.0001. slope=
−1.02 (95% CI −1.27 to −0.76). Life expectancy at birth is based on
the table “US States ranked by life expectancy” in Lichtenberg, F.
2007. Why Has Longevity Increased More in Some States than in
Others? The Role of Medical Innovation and Other Factors.
9 Arizona
and Washington, DC were not included in the cited table and are
excluded here as well. Data on Infant Mortality Rates were obtained
from the National Center for Health Statistics, CDC. Deaths, age-
adjusted death rates, and life expectancy at birth, by race and sex;
and infant mortality rates, by race: United States, final 2003 and
preliminary 2004.
11
679 Baker and Fugh-Berman: Do New Drugs Save Lives? JGIMamong states could have a substantial impact on the indices. A
10% increase in use of hydrocodone/acetaminophen could
lower a state’s Medicaid vintage by 0.1 year — a very large
decline given the limited variation across states.
Opiates are often used in the treatment of cancer and
chronic pain. Rather than shortening lives, older drugs may
simply be more commonly used by people with life-shortening
illnesses — another example of reverse causation.
IMPLAUSIBLE ASSOCIATIONS
Lichtenberg’s analyses linked increased productivity with the
use of new drugs, but found no association with education.
Increased incomes, however, were associated with shorter lives
(see Table 1). Although health insurance coverage was not
found to be associated with longevity, coverage was associated
with increased productivity and decreased health care expen-
ditures. Contrary to a large body of literature correlating longer
lives with higher incomes and socioeconomic status,
13,18–21
Lichtenberg’s regressions also show a strong negative correla-
tion between per capita income and life expectancy both at
birth and at age 65 (see Table 1). Lichtenberg concludes that
rising income between 1991 and 2004 reduced life expectancy
at birth by almost a year (0.86 years) and life expectancy at age
65 by six months (0.49 years).
Lichtenberg cites several papers to support his finding that
higher income lowers life expectancy, but the cited papers
actuallyfocused on cyclical changes in income. Withina country,
higher income that is associated with more people working or
more people working longer hoursdoes lead to transiently higher
death rates.
22,23 However, these studies examined how changes
in death rates respond to departures from the normal trend in
growth of income, and do not claim to show that life expectancies
decline as countries become wealthier.
Lichtenberg’s analysis may have confused the cyclical,
short-term income effects that are highly correlated with
specific years with the impact of a long-term trend increase
in income. Changes in life expectancy would be more highly
correlated with long-term income growth. The impact of rising
income was most likely captured by the year variables
(coefficients of which were not included.) Including year
variables in a regression will likely pick up much of the
increase in life expectancy associated with a rising income
trend and could lead to the erroneous conclusion that
increased income shortens lives.
The conclusion that new drugs enhance growth in produc-
tivity (measured as output per worker per year) is based on
Medicaid data; Medicare data showed no correlation. The
regression that addresses productivity and categories of health
care spending indicates that a one-year increase in drug
vintage raises productivity by 1.1% (See Table 1, column 3).
Extrapolated over the 13-year period of Lichtenberg’s analysis,
the results imply that newer drugs accounted for a 12.5
percentage point increase in productivity, or nearly half of
total productivity growth (27.0%, based on a 50.3% increased
output
24 and an 18.3% increase in the number of employed
persons — the denominator in Lichtenberg’s productivity
term).
25 This result is implausible.
Other implausible results include Lichtenberg’s findings
that education was unrelated to productivity, and that health
insurance reduces health care expenditures while increasing
productivity. The positive association between education and
productivity is as strong as an association can be.
26
Lichtenberg’s findings that health insurance coverage had a
marginally significant positive relationship with productivity
imply that a 10-percentage point increase in health insurance
coverage is associated with a 1.4% rise in productivity. Given
current levels of gross domestic product, this would imply that
a 10% increase in coverage would increase output by almost
$200 billion annually. This result is absurd, because it implies
that relatively small increases in health insurance coverage
lead to huge jumps in economic output.
The highly significant association between health insurance
coverage and reduced health care expenditures (see Table 1)
implies that a 10-percentage point increase in health insur-
ance coverage could reduce total health care spending 4.2%. At
current levels of health care spending, this implies that
expanding health insurance coverage by 10% would save the
country more than $80 billion a year. To the contrary, research
shows that health care expenses increase with expanded
insurance coverage.
27–29
A peculiar relationship between drug spending and Medi-
care drug vintages calls into question the ability of these
indices to reflect new drug use. While the Medicaid drug
vintages show, predictably, that increased use of new drugs is
Table 1. Estimated Effects of Changes in Drug Vintage* or Population Characteristics
Change in Life
Expectancy
Change in Productivity Change in Expenditures
From
Birth
From
Age 65
Drug Home
Health Care
Nursing
Home
Hospital Physician Total
1-y increase Medicaid drug vintage 0.16 y 0.09 y 1.1% 3.5% 9.0% 2.0% NS −4.0% NS
1-y increase Medicare drug vintage 0.03 y 0.01 y NS −0.3% NS 0.5% −0.3% NS NS
0.1 unit increase in education index** NS NS NS 1.6% −2.6% 0.6% 0.6% 1.6% 1.1%
10 percentage point increase in number
of people with health insurance coverage
NS NS 1.4% NS 21.9% 5.7% −2.3% −10.6% −4.2%
10% increase in income −0.16 y −0.09 y 6.5% NS 7.1% −6.4% 4.7% 4.8% 2.7%
Source: Lichtenberg, F. 2007. Why Has Longevity Increased More in Some States than in Others? The Role of Medical Innovation and Other Factors
9
The table is based on Table 7, which shows regression results using the fixed-weight Medicaid drug vintage index
9
* Vintage is defined as the year that the active ingredients in prescription drugs were first approved by the FDA
** In Lichtenberg’s analysis, education index is “an index of mean educational attainment of residents of state i in year t”
NS denotes non-significant at the P<0.05 level
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associate increased use of new drugs with reduced drug
spending. A review of Lichtenberg’s regressions (Table 1) shows
that a one-year increase in Medicare drug vintage is associated
with a 0.3% decline in per capita drug spending. Although it
seems implausible that more rapid adoption of new drugs
would reduce drug expenditures, this anomaly is not
addressed in the text.
CONCLUSION
The report in question purports to support the concept that
new drugs save lives. However, the analysis fails to control for
differences among statesininfantmortalityrates,demographics,
or causes of death. Inadequate surrogate measures of health
status are used, and reverse causation could explain several key
findings.
In economic analyses, a statistical regression stands or falls
in its entirety. A regression that passes inspection for internal
validity should be tested for its ability to withstand manipula-
tion; for example, removing a variable, splitting a time period,
or running the regression in two halves should not qualita-
tively change the results of a robust regression. Lack of
internal consistency indicates that there is something wrong.
In the Lichtenberg analysis, the negative relationship be-
tween income and life expectancy, the finding that health
insurance coverage lowers costs while increasing productivity,
and the lack of a relationship between education and produc-
tivity are all anomalous results inconsistent with a large body
of previous research. The most likely explanation is that the
regressions in this analysis were improperly performed.
Previous studies by Lichtenberg have also been criticized.
4–6
Two previous studies, using Medical Expenditure Panel Survey
(MEPS) data, concluded that replacing older drugs with newer
drugs would save money. The first study
30 was criticized for a
cross-sectional design inappropriate for determining cause
and effect.
4 Additionally, the use of prescriptions as a unit of
analysis rather than people meant that the death of a person
using ten drugs would have been counted as ten deaths.
5 The
second study (NBER) failed to control for prior health status
and other variables.
4 An independent reanalysis, using the
same data and methodologies in conjunction with more
accurate drug approval dates and the consideration of plausi-
ble alternative assumptions, could not confirm Lichtenberg’s
conclusions.
4 An analysis of cardiovascular drugs that used
the same MEPS data set found no association between the
use of newer drugs and non-drug expenditures after control-
ling for the number of drugs or the mix of drugs of different
ages.
6
Lichtenberg’s claims that adopting new drugs saves money,
increases life expectancy, and increases productivity are
unreliable and should not be considered in health policy
decisions. Moreover, while some new drugs are therapeutic
advances, others are not. For example, the federally-funded
ALLHAT study found that chlorthiazide, an older, inexpensive
diuretic, was superior to new drugs for treating hyperten-
sion.
30 The CATIE study, also government-funded, found that
older antipsychotics are as effective as newer ones for treating
schizophrenia.
33,34
Also, newer drugs may amplify risks rather than benefits.
Novel drugs carry more risks than older drugs because
problems associated with long-term use or in special popula-
tions (for example, the elderly) are revealed only after a drug is
in widespread use.
35 Half of drug withdrawals or black box
warnings occur within two years of approval.
36
The Lichtenberg study argues that there have been very
large returns from the development of new drugs in the form of
longer life expectancy and in the form of reduced non-drug
health care costs and increased productivity. The implication
is that the current model of drug development and financing is
extremely successful and that altering it, for example through
the bulk purchases of drugs in the Medicare prescription drug
benefit, could seriously undermine the further development of
new drugs.
Our critique shows that Lichtenberg’s methods are seriously
flawed and his conclusions are therefore unsupportable. In the
absence of more compelling research on the impact of newer
drugs, policymakers should actively seek ways to contain
spending on novel pharmaceuticals. Prescription drugs are
the most rapidly growing component of health care costs and
will impose a major burden on government budgets and the
economy as a whole if they are not reined in.
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